Journals / İbn-i Sina Tıp Dergisi / 2001 / Cilt: 6 - Sayı: 2

The comparation efficiency of cefepime versus ceftazidime at the patients with neutropenic sepsis in childhood

Çocukluk çağındaki nötropenik sepsis tedavisinde sefepimin etkinliğinin seftazidim ile karşılaştırılması

Pages
101–106
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion; we think that empiric use of Cefepime is as effective and safe as ceftazidime in the treatment of febrile neutropenic children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This prospective and randomized trial was performed to evaluate the effect of empiric using Cefepime and Amikacin in children with neutropenic septicaemia.
📊
Key Findings & Data:The patients in Group I (n = 16) were aged between 6-14 (8.3$\pm$3) years, and the patients the patients in Group II (n = 16) aged between 5-17 (6.7±5.2) years.
💡
Conclusion & Impact:In conclusion; we think that empiric use of Cefepime is as effective and safe as ceftazidime in the treatment of febrile neutropenic children.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Seftazidim · Sepsis · Sefalosporinler

Abstract

This prospective and randomized trial was performed to evaluate the effect of empiric using Cefepime and Amikacin in children with neutropenic septicaemia. Thirty two febrile neutropenic patients were included into the study and divided into two groups. The patients in Group I (n = 16) were aged between 6-14 (8.3$\pm$3) years, and the patients the patients in Group II (n = 16) aged between 5-17 (6.7±5.2) years. Cefepime (100mg/kg/d,q12h plus Amikacin (15mg/kg/d, q12h were empirically given to the patients in group I, and Ceftazidime (40 mg/kg/d, q6h) plus Amikacin (15 mg/kg/d, q12h to the patients in group II. The fever decreasing response rates to both therapies were 50% in Group I and 37% in Group II without adding vancomycine or amphotericine-B. The bacterial eradication rates were 75% in each grouup. Both groups were compared with the criteria of "Fever Period" and "Neutropenia Period". Although, significant differences were not found between Fever Period and Neutropenia Period of Groups (p>0.05), the patients in cefepime+amikacin groups showed shorter Fever Period and Neutropenia Period. In conclusion; we think that empiric use of Cefepime is as effective and safe as ceftazidime in the treatment of febrile neutropenic children.

Özet

Bu çalışmada nötropenik sepsisli çocuklarda sefepim + amikasin ampirik kullanımının etkinliği prospektif, rastgele örnekleme yöntemi kullanılarak araştırıldı. Otuz iki nötropenik sepsisli hasta çalışmaya alındı ve iki gruba bölündü. Grup I yaşları 6-14 (8,3±3) arası olan 16 çocuktan, grup II ise yaşları 5-17 (6,7+5,2) olan 16 çocuktan oluşmakta idi. Grup I'deki hastalara sepefim 100mg/kg/gün iki dozda ve amikasin 15mg/kg/gün tek dozda, grup II' deki hastalara ise seftazidim 40mg/kg/gün dört dozda ve amikasin 15mg/kg/gün tek dozda ampirik uygulandı. Vankomisin veya amfoterisin B ilave edilmeksizin ateşin normale dönme oranı grup I'de %50, grup II'de % 37 idi. Her iki tedavi grubunda bakteriyel eradikasyon oranı % 75 idi. Her iki grup ateş ve nötropeni periyodu yönünden karşılaştırıldı. Gruplar arasında ateş ve nötropeni periyodu yönünden anlamlı farklılık görülmemesine rağmen (p>0,05), sefepim + amikasin tedavisi alan grup daha kısa ateş ve nötropeni periyoduna sahip idi. Sonuç olarak nötropenik sepsisli çocukların tedavisinde ampirik olarak sefepim kullanımının seftazidim kadar etkili ve güvenli olduğunu düşünmekteyiz.

🔖

Cite This Article

MUTLU, M., YILDIRAN, A., ERDURAN, E. (2001). The comparation efficiency of cefepime versus ceftazidime at the patients with neutropenic sepsis in childhood. İbn-i Sina Tıp Dergisi, Cilt: 6 - Sayı: 2, 101–106. https://ajindex.com/articles/284757

References (4)

  1. Bodey G. P., Buckley M., Satho Y.S., Freirech F.S. Quantitative relationships between circulating leukocytes and infection in patients with acute lukaemia. Ann of Inter Med; 64; 328-340, 1996
  2. Pizzo P.A. Management of fever in patients with cancer and treatment induced neutropenia. New Engl Med; 328: 1323-1332, 1993 3. Pizzo P.A., Meyers J., Freifeld A.G., Walsh T. Infections in the cancer patients, In Cancer Principles and Practice of Clinical Oncology, 5th edn, (De Vita VJ, Holman S., Rosenberg SA eds), J.B. Lippincott-Raven Company, Philadelphia, 1997, pp. 2659-2704, 4. Cohen J., Worsley A.M., Goldman J.M., Donnelly J.P., Gatovsky D., Galton D.A.G. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet; 8361: 1452-1454, 1983 5. Hughes W.T., Armstrong D., Bodey G.P., Brown A.E., Edwards J.E., Feld R., Pizzo P., Rolston K.V.I., Shenep J.L., Young L.S. Guidelines from the Infectious Diseases Society of America. 1997 Guildenlines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Patients with Unexplained Fever. Clin Infect Dis; 25: 551-573, 1997 6. Kern W., Kurrle E., Schmeiser T. Streptococcal bacteremia in adult patients with leukameia undergoing aggressive chemotherapy. A reviev of 55 cases. Infection; 18: 138-145, 1990 7. Patrick C.C., Coagulase – negative staphylococci: Pathogens with increasing clinical significance. Pediatr; 116: 497-507, 1990 8. Bodey G.P. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M.D., Anderson Hospital. Rew Infect Dis; 11: 1582-1590, 1989 9. Rolston K.V., Berkey P., Bodey G.P., Anaissie E.J. Kharden N.M., Joshi J.H., Keathing M.J., Holmes F.A., Cabanillas F.F., Eiting L.A., comparsion of imipenem to ceftazidime with or without amicasin as empiric therapy in fibrile neutropenic patients. Arch Intern Med; 152: 283-291, 1992 10. Rubin M., Hethron J.W., Marshall D., Gress J., Steinberg S.M., Pizzo P.A. Grampositive Infections and the Use of Vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med; 108: 30-35, 1988
  3. Hussein A.M., Elkordig M., Peters W.P. The use of growth factors with antibiotics in the setting of neutropenic fever. Am Med; 100: 15-17, 1996
  4. Wiley J.M., Smith N., Leventhal B. G., Graham M.L., Strauss L.C., Hurwitz C.A., Modlin J.M., Mellits D., Baumgardner R., Corden B.J., Civin C.I. Invasive fungal diseases in paediatric acute leukaemia patients with fever and neutropenia during induction ch